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Abstract 
Background: Dopamine D2 receptor (DRD2) is thought to be critical in regulating the 
dopaminergic pathway in the brain which is known to be important in the aetiology of 
schizophrenia.  It is therefore not surprising that most antipsychotic medication acts on the 
Dopamine D2 receptor.  DRD2 is widely expressed in brain, levels are reduced in brains of 
schizophrenia patients and DRD2 polymorphisms have been associated with reduced brain 
expression.  We have previously identified a genetic variant in DRD2, rs6277 to be strongly 
implicated in schizophrenia susceptibility.   
Methods: To identity new associations in the DRD2 gene with disease status and clinical 
severity, we genotyped seven single nucleotide polymorphisms (SNPs) in DRD2 using a 
multiplex mass spectrometry method.  SNPs were chosen using a haplotype block-based 
gene-tagging approach so the entire DRD2 gene was represented.   
Results: One polymorphism rs2734839 was found to be significantly associated with 
schizophrenia as well as late onset age.  Individuals carrying the genetic variation were more 
than twice as likely to have schizophrenia compared to controls.   
Conclusions: Our results suggest that DRD2 genetic variation is a good indicator for 
schizophrenia risk and may also be used as a predictor age of onset.   
 
Keywords:  schizophrenia; genetics; polymorphism; dopamine pathway; Dopamine D2 
receptor 
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Introduction  
Schizophrenia is a severe psychiatric illness affecting one percent of the population.  The 
genetic risk for schizophrenia is high with some studies predicting up to 80% heritability 
(McGuffin and Gottesman, 1999; Sullivan et al., 2003).  The aetiology of schizophrenia has 
been associated with brain dopaminergic activity.  The dopamine D2 receptor (DRD2) gene is 
located on chromosome 11q22-23 (Grandy et al., 1989) and is thought to play a pivotal role 
in the dopamine pathway.  A genome-wide linkage meta-analysis has also implicated DRD2 
in risk for schizophrenia (Lewis et al., 2003).  We have previously reported the 957C-allele 
of a DRD2 polymorphism (rs6277) to be significantly associated with schizophrenia 
(Lawford et al., 2005).  Several studies have confirmed this association (Betcheva et al., 
2009; Dubertret et al., 2010; Fan et al., 2010; Hanninen et al., 2006; Hoenicka et al., 2006) 
including a meta-analysis (Monakhov et al., 2008).  The T-allele of rs6277 polymorphism has 
been shown to be associated with decreased DRD2 mRNA translation and stability as well as 
reduced dopamine-induced up-regulation of D2 receptors (Duan et al., 2003).  In healthy 
individuals the T-allele is also associated with increased striatal D2 receptor binding 
(Hirvonen et al., 2005).   
There have also been other DRD2 polymorphisms found to be associated with schizophrenia 
including the well studied deletion polymorphism rs1799732 in the promoter of DRD2.  
Functional studies have shown that it is associated with lower DRD2 promoter activity 
(Arinami et al., 1997).  A non-synonymous polymorphism rs1801028 was one of the first 
polymorphisms showing association with schizophrenia (Arinami et al., 1994) but other 
studies have failed to replicate this result.  Interestingly, a meta analysis did support the 
association (Glatt et al., 2003).    
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In summary a number of polymorphisms in DRD2 have been identified that are associated 
with schizophrenia but their individual effects on risk for schizophrenia are small.  To 
identify novel polymorphisms associated with schizophrenia and replicate previous 
association studies, seven SNPs in DRD2 were selected that mark haplotype blocks, covering 
the entire DRD2 gene.  Following genotyping in an Australian population these SNPs were 
analysed for association with schizophrenia.   
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Materials and Methods 
Participants 
The study included 157 Caucasian schizophrenia patients and 250 unrelated Caucasian 
controls.  Subjects were aged between 18 and 65 years.  Diagnostic and Statistical Manual of 
Mental Disorders-IV (DSM-IV) (American Psychiatric Association, 1994) diagnosis of 
schizophrenia was confirmed by at least two independent psychiatrists.  These patients had 
never been diagnosed with other psychiatric disorders, including schizoaffective disorder, 
major depressive episode with psychotic features, or bipolar disorder.  No patients were 
treated with antidepressants, anxiolytic agents, or mood-stabilizing psychotropic medications 
and all were maintained on a constant dose of antipsychotic medication for a minimum of 
three weeks.  There were 23 females and 134 males in the group diagnosed with 
schizophrenia with a mean age of 36.2 years (s.d.  12.1 years).  The mean age of patients at 
first diagnosis (onset of psychotic symptoms) was 23.2 years (s.d.  7.3 years).  They were 
being treated at the Royal Brisbane and Women’s Hospital, The Park Psychiatric Unit, and 
the Valley Community Psychiatric Centre.  The clinical sample was composed of 65 
inpatients and 92 outpatients. All patients were administered the Positive and Negative 
Symptom Scale (PANSS) (Peralta and Cuesta, 1994) to assess severity of psychotic features.  
The PANSS total mean score was 45.13, SD. 13.69.  This clinical sample was a group who 
had lived with schizophrenia for an average of 13 years since diagnosis continued to 
experience positive and negative symptoms despite treatment with antipsychotic medication.  
Mean length of illness was 13.39 years, SD 10.91.  In addition, the schizophrenia group 
contained a high proportion of individuals with a relatively severe history and/or a familial 
risk for psychosis. 
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The control group consisted of 102 females and 148 males, with a mean age of 36.8 years 
(s.d. + 12.8 years).  The control group was composed of volunteers from the general public, 
hospital nursing and medical staff, and university staff and students.  Formal screening for 
schizophrenia or other psychological disorders was not undertaken in the control population.  
As such, the controls represent an unselected control group.  To minimise population 
stratification bias, both control and clinical subjects were recruited in the Brisbane region (a 
city of approximately 2 million inhabitants on the East Coast of Australia) and all were of 
British or European descent. 
Ethics approval was obtained from all institutions involved. 
Selection of SNPs 
Using the International HapMap Project (HapMap) phase II (Frazer et al., 2007), seven tag-
SNPs in DRD2 with a minor allele frequency of 0.15 were selected.  Tag-SNPs were 
identified using the pair-wise option of Tagger with a threshold of r2 > 0.8.   
Genotyping 
Oragene kits were used to extract DNA from saliva samples.  Samples were genotyped using 
a homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome 
Research Facility.  The hME assay is based on the annealing of an oligonucleotide primer 
(hME primer) adjacent to the SNP of interest.  The addition of a DNA polymerase along with 
a mixture of terminator nucleotides allows extension of the hME primer through the 
polymorphic site and generates allele-specific extension products, each having a unique 
molecular mass.  The resultant masses of the extension products are then analysed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
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a genotype is assigned in real time.  The hME assay was performed in multiplex with up to 
36 reactions in a single well. 
The genotyping fail rate was 4% for rs1752947; 6% for rs1760161; 4% for rs1800499; 5% 
for rs2734839; 3% for rs4245147; 3% for rs6275 and 4% for rs7131056.  The genotyping of 
several other SNPs including DRD2 rs6277 were independently verified by other methods 
such as real-time PCR with a concordance rate of 96.6 %.  Genotypes were determined by 
investigators blinded for clinical diagnoses.   
Statistical Analysis 
A Pearson’s chi-squared test was performed to identify statistical associations between 
alleles/genotype and schizophrenia status.  Odds ratios (OR) were also calculated.  Tests were 
performed on both genotype and allele data.  Statistical tests were performed using the 
COMPARE2 program from the WinPepi suite of epidemiology programs (Abramson, 2004) 
and SPSS version 16.0.  Hardy-Weinberg equilibrium (HWE) was computed using Utility 
Programs for Analysis of Genetic Linkage (Ott, 1988).  The analysis of genotypes under a 
recessive model involved pooling the low-risk homozygotes and the heterozygotes and 
comparing frequencies with the high-risk homozygotes, i.e. OR > 1.  Correction for multiple 
testing was conducted using the Benjamini-Hochberg method (Benjamini and Hochberg, 
1995).  Linkage disequilibrium was calculated using JLIN version 1.6.0 (Carter et al., 2006) 
 
Results 
A comprehensive genotype analysis of DRD2 and its association with schizophrenia was 
undertaken using a haplotype block-based gene-tagging approach.  A total of seven tag-SNPs 
that span from the 3'-end to the 5'-end of the gene were genotyped in a sample of 157 
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schizophrenia patients and 250 controls.  One SNP was found to be significantly (p = 0.0064) 
associated with schizophrenia at the allele (Table 1).  Rs2734839 was also significant at the 
genotype level (Table 2).  Rs2734839 survived correction for multiple testing (corrected α-
value was 0.012) 
In the control and schizophrenia samples strong linkage disequilibrium (LD) was observed 
between rs2734839 and the previously reported rs6277 SNP (D' = 1 in the schizophrenia 
population; D' = 0.98 in the control population).   
Genotype frequencies indicated that all polymorphisms were in HWE in both cases and 
control samples (rs2734839 controls χ2 = 1.63 p = 0.20 schizophrenia χ2 = 0.066 p = 0.80) 
Examination of the genotype odds ratios (OR) of the rs2734839 SNP suggests a recessive 
pattern of inheritance.  The heterozygous OR and the OR for the low-risk homozygote are 
approximately one (Table 2).  Subsequently rs2734839 was found to be associated with 
schizophrenia when analysed under a recessive model by pooling genotypes (p = 0.010). 
In order to evaluate whether there was any sexual dimorphism in the population, the male 
schizophrenia patients were analysed separately from the female patients.  At the genotype 
level rs2734839 showed association with disease with a slightly weaker p-value (Pearson χ2 = 
7.375 p = 0.025) for the males.  The male schizophrenia samples remained in HWE.  The 
remaining female cases were too small in number to analyse meaningfully.   
A number of clinical parameters were also examined for association with DRD2 variation.  
These included onset age, number of hospital admissions, family history, PANSS subscales, 
PANSS total, BARN subscales, BARN total, AIMS subscales, AIMS total, GHQ subscales, 
GHQ total and TMTA.  A significant association was found for onset age and rs2734839.  No 
other associations were observed.  Analysis of variance revealed significant differences in 
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onset age between genotypes (p = 0.011, F = 4.614).  Patients with the GG and GA genotypes 
had a mean onset age of 24.03 (95% C I= 20.87-27.19) and 24.25 (95% CI = 22.68-25.81) 
years whereas patients carrying the AA genotype had a mean onset age of 20.11 years (95% 
CI = 18.14-22.07).  Post-hoc pairwise comparisons including Tukey and Bonferroni were 
undertaken to test differences between groups.  Schizophrenia patients carrying the GA 
genotype had later schizophrenia onset age than those carrying the AA genotype (Tukey P = 
0.011, Bonferroni P = 0.012).   
For the six polymorphisms that did not show a significant association we did not have enough 
power (<0.80) to detect association with our sample size using retrospective power 
calculations for a case-control study in syntax SPSS version 18 because the odds ratios were 
so low(between 1.06 and 1.29).  In fact a sample size ranging from 1000-19000 would be 
required to show any significance for these six polymorphisms with schizophrenia.  It is most 
likely that the odds ratios are low because there is no biological role for these SNPs.   
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Discussion 
Analysis of seven tag-SNPs in DRD2 revealed associations with schizophrenia at the 
genotype and allele level for rs2734839 in an Australian schizophrenia cohort.  Given the 
number of discordant gene association studies with schizophrenia it is likely to be a complex 
disorder with both environment and genetics playing a role.  Although the genetic risk is high 
at 80% (McGuffin and Gottesman, 1999; Sullivan et al., 2003) it is likely that no one gene 
accounts for this risk and a number of polymorphisms contribute.  In a previous study we 
found an association with the rs6277 polymorphism and schizophrenia (Lawford et al., 2005) 
and this association has been replicated by others (Betcheva et al., 2009; Dubertret et al., 
2010; Fan et al., 2010; Hanninen et al., 2006; Hoenicka et al., 2006; Monakhov et al., 2008).  
The positive association with rs2734839 that we observed in this study appears novel.  
Interestingly, rs2734839 is in nearly complete LD with rs6277.  Although rs6277 does not 
result in a non-synonymous polymorphism it does appear to have functional consequences on 
the protein translated (Duan et al., 2003; Hirvonen et al., 2005).  There is still the possibility 
that rs2734839 is a functional SNP as other intronic SNPs in DRD2 have been shown to have 
functional effects.  The rs2283265 SNP and rs1076560 which are both intronic affect the D2 
receptor long isoform and D2 receptor short isoform ratio of splice variants (Zhang et al., 
2007).  The same SNPs were found to modulate working memory and attention (Zhang et al., 
2007).  Therefore, the association we found between rs2734839 and schizophrenia first needs 
to be replicated in another sample set and secondly tested for functional effects.   
Our results are similar to the findings of Dubertret et al. (Dubertret et al., 2010) who 
identified a SNP (rs2242592) in the intergenic region of DRD2 that is in strong LD with 
rs6277.  As they observed a stronger association with rs2242592 than with rs6277, they 
concluded that an unknown functional SNP in LD with rs2242592 is likely to be identified in 
the future.  It is possible that a functional SNP exists in non-coding region and has been 
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overlooked by focus on protein coding regions.  Evidence is now showing that non-coding 
RNAs are also regulators of human disease (Taft et al., 2010).   
Like Fan et al. (Fan et al., 2010) we did not find an association with rs6275 and 
schizophrenia.  It is likely that there is no biological role for this SNP in schizophrenia as 
there was no indication of a bias toward schizophrenia (OR = 1.18).  Contrary to our 
observations, this polymorphism was shown previously to be associated with schizophrenia 
and the same study found it interacts with rs4680 in COMT to increase schizophrenia 
susceptibility (Gupta et al., 2009).  Earlier studies in an Indian and Russian population also 
found an association with schizophrenia (Kukreti et al., 2006; Monakhov et al., 2008), 
however both studies observed departure from HWE in the case population.   
The rs2734839 polymorphism was also found to be significantly associated with later onset 
age.  In patients carrying the associated allele (G) onset age was delayed by an average of 4 
years.  The average onset age for the AA genotype was only 20 years suggesting that this 
polymorphism is associated with a youth onset subset of schizophrenia.  Other studies have 
also observed polymorphisms to be associated with onset age in schizophrenia.  One of these 
studies suggested that a polymorphism in the CCR5 gene is a susceptibility factor for 
schizophrenia with late onset or alternatively the polymorphism may act as a modifier by 
delaying the onset of schizophrenia without affecting disease susceptibility (Rasmussen et al., 
2006).  Our study is different from this one in that they did not find a significant association 
between the CCR5 polymorphism and schizophrenia, only onset age.  Therefore in our study 
it is likely that the rs2734839 polymorphism is associated with schizophrenia but only in a 
subset of patients with delayed onset.  For the early onset group (mean age 20) other genes 
are likely to be responsible.   
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Our significant association between the rs2734839 polymorphism and schizophrenia needs to 
be replicated in a larger sample size and other defined ethnic groups.  Our study does not rule 
out population stratification but the affects are likely to be small as patients and controls were 
all Caucasians from Australia.  The significant association seen with rs2734839 and 
schizophrenia onset age must be seen as exploratory until it is tested in a larger sample set of 
equal numbers of cases and controls.  Unfortunately we did not have access to a defined 
group of late onset patients (onset age over 40 years).  Our patient group was mainly early 
onset with 23 years the average age of first diagnosis.  Ideally this study would need to be 
repeated with a defined set of early and late onset patients.  
Conclusions 
We have found a significant association between schizophrenia and a polymorphism 
rs2734839 in the DRD2 gene.  This same polymorphism was also shown to be associated 
with schizophrenia onset age.  The DRD2 region has shown consistent evidence for 
association with schizophrenia and it is likely that many genetic variants interact together 
modulating dopamine signalling.   
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Table 1 
Allele association of 7 DRD2 SNPs with schizophrenia 
* Nucleotide position on the chromosome 11 reference sequence 
† p-value determined by Pearson’s chi-squared test 
SNP ID 
Allele 
frequency Position* 
SNP  
details χ
2 p-
value† 
Odds 
Ratio  95% CI 
rs17529477 
control 
SZ 
A 
152 
85 
G 
318 
225 
112822277 Intron 1 2.139 0.144 1.27 0.91-1.76 
rs17601612 
control 
SZ 
C 
187 
108 
G 
269 
200 
112822955 Intron 1 2.740 0.098 1.29 0.94-1.76 
rs4245147 
control 
SZ 
C 
239 
140 
T 
245 
168 
112823217 Intron 1 1.162 0.281 1.17 0.87-1.58 
rs7131056 
control 
SZ 
A 
194 
132 
C 
276 
178 
112834984 Intron 1 0.131 0.718 1.06 0.78-1.43 
rs1800499 
control 
SZ 
A 
16 
12 
G 
448 
300 
112792904 Exon 2  0.085 0.771 1.12 0.48-2.56 
rs2734839 
control 
SZ 
A 
288 
158 
G 
180 
148 
112791700 Intron 3 7.433 0.0064 1.50 1.11-2.03 
rs6275 
control 
SZ 
C 
335 
205 
T 
143 
103 
112788687 Exon 5  1.083 0.298 1.18 0.85-1.62 
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Table 2 
Genotype association of rs2734839 with schizophrenia. 
Polymorphism Genotype counts (%) p-value* 
rs2734839 AA GA GG  
Control 84 (35.9) 120 (51.3) 30 (12.8) 0.016 
0.005† schizophrenia 40 (26.1) 78 (51.0) 35 (22.9) 
Odds Ratio‡ 
   (p-value) 
1 
 
1.37 
(0.388) 
2.45 
(0.008) 
 
* p-value determined by Pearson’s χ2 test 
† p-value determined using the extended Mantel-Haenszel test for trend 
‡ OR, with respect to the genotype that was not associated with schizophrenia 
 
